Q1: Does that addressable market incorporate impact of generic price erosion?.
Q2: How many competitors are there?
Q3: Pharma co's generally spend 7%-8% of annual revenues on R&D. Of course, that's expenditure today, for (uncertaint) revenue tomorrow. So how much could we expect the partner co to pay in royalties? Their gross-margins are about 40%-50%. Their SG&A is about 20%-27% of revenues. Thus 15% maybe? 20%? Honest question.
Q1: Does that addressable market incorporate impact of generic...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
